Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jan, 2015 | Pages:
61 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Obsessive-Compulsive Disorder - Pipeline Review, H1 2015 Summary Global Markets Direct's, 'Obsessive-Compulsive Disorder - Pipeline Review, H1 2015', provides an overview of the Obsessive-Compulsive Disorder's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Obsessive-Compulsive Disorder, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Obsessive-Compulsive Disorder and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Obsessive-Compulsive Disorder - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Obsessive-Compulsive Disorder and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Obsessive-Compulsive Disorder products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Obsessive-Compulsive Disorder pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Obsessive-Compulsive Disorder - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Obsessive-Compulsive Disorder pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Obsessive-Compulsive Disorder Overview 7 Therapeutics Development 8 Pipeline Products for Obsessive-Compulsive Disorder - Overview 8 Pipeline Products for Obsessive-Compulsive Disorder - Comparative Analysis 9 Obsessive-Compulsive Disorder - Therapeutics under Development by Companies 10 Obsessive-Compulsive Disorder - Therapeutics under Investigation by Universities/Institutes 11 Obsessive-Compulsive Disorder - Pipeline Products Glance 12 Late Stage Products 12 Clinical Stage Products 13 Early Stage Products 14 Unknown Stage Products 15 Obsessive-Compulsive Disorder - Products under Development by Companies 16 Obsessive-Compulsive Disorder - Products under Investigation by Universities/Institutes 17 Obsessive-Compulsive Disorder - Companies Involved in Therapeutics Development 18 AbbVie Inc. 18 Addex Therapeutics Ltd 19 C4X Discovery Ltd 20 F. Hoffmann-La Roche Ltd. 21 Heptares Therapeutics Ltd. 22 Novartis AG 23 Omeros Corporation 24 Rottapharm SpA 25 Sellas Inc. 26 Obsessive-Compulsive Disorder - Therapeutics Assessment 27 Assessment by Monotherapy Products 27 Assessment by Target 28 Assessment by Mechanism of Action 30 Assessment by Route of Administration 32 Assessment by Molecule Type 33 Drug Profiles 34 ADX-71743 - Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 ADX-88178 - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 bitopertin - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 CR-5542 Series - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 CR-5772 Series - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 dipraglurant IR - Drug Profile 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 fluvoxamine maleate - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 mavoglurant - Drug Profile 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 methoxycoronaridine - Drug Profile 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 OMS-527 - Drug Profile 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 Small Molecule to Antagonize Orexin 1 for Addiction and Compulsive Disorders - Drug Profile 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 Small Molecules to Antagonize Orexin-1 Receptor for CNS Disorders - Drug Profile 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 Small Molecules to Inhibit DAT and SERT for CNS Disorders - Drug Profile 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 zolpidem tartrate - Drug Profile 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 Obsessive-Compulsive Disorder - Recent Pipeline Updates 51 Obsessive-Compulsive Disorder - Dormant Projects 57 Obsessive-Compulsive Disorder - Discontinued Products 58 Obsessive-Compulsive Disorder - Product Development Milestones 59 Featured News & Press Releases 59 Mar 19, 2013: Omeros Elucidates Mechanism Of PDE7 Inhibitors In Addiction 59 Appendix 60 Methodology 60 Coverage 60 Secondary Research 60 Primary Research 60 Expert Panel Validation 60 Contact Us 61 Disclaimer 61
List of Tables Number of Products under Development for Obsessive-Compulsive Disorder, H1 2015 8 Number of Products under Development for Obsessive-Compulsive Disorder - Comparative Analysis, H1 2015 9 Number of Products under Development by Companies, H1 2015 10 Number of Products under Investigation by Universities/Institutes, H1 2015 11 Comparative Analysis by Late Stage Development, H1 2015 12 Comparative Analysis by Clinical Stage Development, H1 2015 13 Comparative Analysis by Early Stage Development, H1 2015 14 Comparative Analysis by Unknown Stage Development, H1 2015 15 Products under Development by Companies, H1 2015 16 Products under Investigation by Universities/Institutes, H1 2015 17 Obsessive-Compulsive Disorder - Pipeline by AbbVie Inc., H1 2015 18 Obsessive-Compulsive Disorder - Pipeline by Addex Therapeutics Ltd, H1 2015 19 Obsessive-Compulsive Disorder - Pipeline by C4X Discovery Ltd, H1 2015 20 Obsessive-Compulsive Disorder - Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 21 Obsessive-Compulsive Disorder - Pipeline by Heptares Therapeutics Ltd., H1 2015 22 Obsessive-Compulsive Disorder - Pipeline by Novartis AG, H1 2015 23 Obsessive-Compulsive Disorder - Pipeline by Omeros Corporation, H1 2015 24 Obsessive-Compulsive Disorder - Pipeline by Rottapharm SpA, H1 2015 25 Obsessive-Compulsive Disorder - Pipeline by Sellas Inc., H1 2015 26 Assessment by Monotherapy Products, H1 2015 27 Number of Products by Stage and Target, H1 2015 29 Number of Products by Stage and Mechanism of Action, H1 2015 31 Number of Products by Stage and Route of Administration, H1 2015 32 Number of Products by Stage and Molecule Type, H1 2015 33 Obsessive-Compulsive Disorder Therapeutics - Recent Pipeline Updates, H1 2015 51 Obsessive-Compulsive Disorder - Dormant Projects, H1 2015 57 Obsessive-Compulsive Disorder - Discontinued Products, H1 2015 58
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
